Polycystic Ovary Syndrome: Effect of Inositols and Lipid Mediators. Pilot Study

Abstract

Objective: to evaluate the effect of the combination of inositiol derivatives and lipid mediators on the metabolic and inflammatory profile of women with polycystic ovary syndrome.Material and Methods: Experimental, prospective and longitudinal study carried out in patients diagnosed with polycystic ovary syndrome (Rotterdam criteria) without treatment or previous dietary intervention. The following nutritional preparations were administered orally daily:• Group B: 4000 mg of myo -inositol + 30 mg of lipinovaThe metabolic profile is compared before and after 4 weeks of treatment in each patient, determining the insulin levels and the HOMA index. The inflammatory profile was analyzed by determining the levels of IL-6 before and after treatment. Results• 41 patients with polycystic ovary syndrome subdivided into 20 from group A and 21 from group B were studied.• Insulin levels before and after treatment were 17.9 +-9.3 SD and 10 +-4.09 SD, respectively, with statistically significant differences. •The HOMA index pre-treatment was 4.1 +-2.1 SD and 2.1+-1.1 SD post-treatment, with significant differences •The level of IL-6 was pretreatment was 3.8 +-1.5 Sd of 2.1 + -1.09 post treatment with significant differences Conclusion:The results of the study show the positive effect of the combined administration of inositolic derivatives and proresolution lipid mediators on the metabolic, clinical and inflammatory profile of patients with polycystic ovary syndrome.